Hematologic Oncology

Two more cancer centers have joined Intel's Collaborative Cancer Cloud data sharing and research platform, the chip maker and the Oregon Health & Science University (OHSU) have announced.

A first-in-man phase I study of CUDC-907, which targets both histone deacetylase and PI3K enzymes, has shown promise in patients with relapsed or refractory multiple myeloma or lymphoma.

The long-term use of romidepsin in a dose-sparing regimen to treat cutaneous T-cell lymphoma may be a useful strategy to try to prolong disease response.

A scoring system including several patient characteristics was found to have significant prognostic value for patients with myelodysplastic syndromes undergoing allogeneic hematopoietic cell transplantation.

Patients with acute myeloid leukemia who have undergone autologous stem cell transplantation and survived without disease recurrence for at least 2 years are still at risk for late recurrences.

The FDA has approved defibrotide sodium (Defitelio) for the treatment of hepatic veno-occlusive disease following hematopoietic stem cell transplantation in both adults and children.

Patients with CML who are treated with dasatinib commonly experience lymphocytosis, and the condition is associated with higher response rates and increased survival in patients who are refractory or intolerant of imatinib.

The FDA has approved two indications of a new formulation of melphalan hydrochloride called Evomela for the treatment of multiple myeloma.

The injectable drug APO866, designed to induce apoptosis, did not have efficacy against cutaneous T-cell lymphoma, according to the results of small study.

Elevated levels of TGF-α and IL-6 in newly diagnosed chronic-phase chronic myeloid leukemia patients were predictive of failure to achieve molecular response.

Early relapse after stem cell transplant was linked with worse overall survival in multiple myeloma patients who received a novel agent prior to transplant.

A study found an increased incidence of non-Hodgkin lymphoma, but no other secondary malignancies, in chronic myeloid leukemia patients treated with imatinib.

Temsirolimus produced some responses in patients with relapsed/refractory primary central nervous system lymphoma, but the responses tended to be short-lived.

Patients with chronic phase CML and pre-existing mild to moderate liver and/or renal dysfunction can be safely treated with frontline nilotinib or dasatinib, according to a new study.

Higher levels of the hormone adiponectin may protect against the development of multiple myeloma in overweight and obese individuals.

Baseline serum levels of the inhibiting inflammatory cytokine interleukin-10 (IL-10) were predictive of prognosis in a group of patients with multiple myeloma.

In light of the recent announcement by Vice President Joe Biden to infuse the US cancer research program with $1 billion, a so-called “Moon Shot” program, we are speaking today with Giulio Draetta, a clinician and cancer researcher at MD Anderson Cancer Center at the University of Texas in Houston, who leads that center’s Moon Shots program.

Although a child’s socioeconomic status did not seem to significantly affect 5-year overall survival ALL, those children who were from high-poverty areas experienced early relapse compared with children who were from low-poverty areas.

Individuals with increased height or body mass index during adolescence showed an increased association with a diagnosis of non-Hodgkin lymphoma.

A phase I trial found that blinatumomab, a bispecific T-cell engager antibody, is feasible with regard to safety for treatment of patients with relapsed or refractory non-Hodgkin lymphoma.

A new personalized DNA-based assay can detect very low levels of persistent disease in chronic myeloid leukemia patients thought to be in deep remission.

Despite similar survival, multiple myeloma patients treated with lenalidomide experienced lower rates of neurologic toxicity than those treated with thalidomide.

Researchers have uncovered the mechanism that causes about one-third of myeloma cases associated with Gaucher disease, showing that myeloma cells target certain lipids that are elevated in the blood of a subset of patients.

A number of clinical and sociodemographic factors, including age and gender, were found to be independently associated with fatigue and depression among cancer patients who were treated with hematopoietic cell transplantation.